Dr Bo Jesper Hansen, M.D., PhD, permanent representative of Orfacare Consulting, is currently Chairman of Karolinska Development AB and is also non-executive Director of a number of biotech and pharma companies including Orphazyme ApS, Newron Pharmaceuticals SpA, CMC AB, Genspera Inc. and Azanta A/S. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International AB until the merger with Biovitrum, forming Swedish Orphan Biovitrum AB (SOBI AB). Dr Hansen was executive Chairman of the Board of SOBI AB. He also was non-executive Director of Gambro until its acquisition by Baxter, and of Zymenex, until its acquisition by Chiesi. Dr Hansen was the Executive Chairman of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical.